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H ereditary hemochromatosis (HH) is agenetically determined disorder charac-
terized by iron overload. The patients present
elevated serum ferritin, high serum iron, and
transferrin saturation greater than 45%. If
untreated, the pathology evolves to dia-
betes, heart failure, arthritis, bronze pig-
mentation of the skin, and liver cirrhosis,
which could degenerate in hepatocellular
carcinoma. Hereditary hemochromatosis was
described in 4 typologies more than 10 years
ago.1 Type 1 is characterized by mutations
in the HFE gene and is the most common
genetic disorder with mild severity. The
classical variations, which constitute the
more frequent genetic background, are
either the homozygous mutation p.C282Y
or the compound heterozygous mutations
C282Y/H63D. Type 2 is the more severe
form of the disorder with the onset in the
first to third decade of life and is defined
as juvenile hemochromatosis. It is charac-
terized by rare mutations in the HAMP
(type 2A) or in the HJV (type 2B) genes.2
Type 3 has early onset and an intermediate
severity and is related to rare mutations in
the TFR2 gene.3 Type IV is also named
ferroportin disease because it has some pe-
culiarities in clinical manifestations and is
determined by rare mutations in the SLC40A1
gene.4 The penetrance of the more common
HH form (type 1) is incomplete among indi-
viduals with genetic predisposition, and var-
iability in the severity of clinical manifestations
is often described. Furthermore, not all
hemochromatosis cases are classifiable as
described above or are explained by muta-
tions in the mentioned genes. The studies
of the HH molecular mechanisms mainly
demonstrated the deregulation of the sys-
temic expression of hepcidin or the lack of
effect on its receptor ferroportin. The vari-
ability of clinical manifestations, which
were the object of numerous studies in the
past decade, is likely explained by both en-
vironmental and genetic factors.5
18F-FDG PET is a diagnostic imaging
applied in oncology, cardiology, and neu-
rology. The liver and brain have elevated
glucose metabolism, and therefore both these
organs are characterized by physiologi-
cally high 18F-FDG uptake. Inflammation
is a pathological condition that augmentsClinical Nuclear Medicine • Volume 41, Nu
Copyrightthe glucose metabolism and the 18F-FDG
uptake; in recent years, its role in inflam-
matory and infectious disease has been
continuously growing.
Recently, we read and appreciated an
interesting contribute by Infante et al6 that
describes the high liver uptake of 18F-FDG
on PET/CT in a 64-year-old white man di-
agnosed with HH. This patient has a his-
tory of non-Hodgkin diffuse large B-cell
lymphoma treated with chemotherapy, ra-
diotherapy, and stem cell transplant. He un-
derwent 18F-FDG PET/CT, and it showed
normal distribution. One month later, pa-
tient complained abdominal pain and fever.
Biochemical parameters showed high level
of serum ferritin (1068 ng/mL; reference
range, 10–120 ng/mL). The analysis of HFE
gene evidenced in the exon 2 the H63D
homozygous mutation. Three months later,
a new 18F-FDG PET/CTwas performed as
a follow-up for his hematological malignancy
without biochemical evidences of tumor
recurrence. PET/CT images revealed high-
glucose metabolism in the liver with homo-
geneous pattern (SUVmax, 19.1) and not
other pathological finding. After 5 months
of follow-up, the patient remained free of
disease, and the authors speculated that
“increased FDG uptake was not due to tu-
mor disease but to liver damage caused by
increased iron deposits probably due to in-
tense hematological therapy.” Another case
of high liver uptake of 18F-FDG in a sec-
ondary hemochromatosis casewas reported
some time ago in this journal.7
The high 18F-FDG uptake due to iron
accumulation could be a very interesting tool
in the diagnosis and management of hemo-
chromatosis, which is the most common
genetic disorder in white people.
The correlation between iron overload
and high 18F-FDG liver uptake should de-
serve further studies in an appropriate cohort
of patients affected by hereditary hemochro-
matosis type 1. Age of onset, sex, and HFE
genetic background (C282Y homozigosity
or C282Y/H63D compound heterozigosity;
H63D homozygous is slightly correlated to
hemochromatosis 1% in males and 0.5% in
females) should be known. Serum ferritin
could be elevated as a consequence of other
factors such as acute or chronic inflamma-
tion, cancer, hepatitis, and hyperferritinemia
cataract syndrome in addition to iron over-
load. Therefore, additional parameters of iron
overload (serum iron and transferrin satura-
tion) should be necessary to study hemochro-
matosis. Biochemical parameters of hepatic
functionality should be dosed to completember 3, March 2016
 © 2016 Wolters Kluwer Health, Inc. All rights resethe clinical hepatic functional profile. The
patients should undergo 18F-FDG PET/CT,
and liver uptake should be correlated with
biochemical parameters of iron overload
and with the amount of the liver iron con-
centration evaluated by liver biopsy. If
18F-FDG uptake depends on iron overload,
scientists could elaborate a mathematical
model to define the correlation. To complete
the studies, a new follow-up 18F-FDG PET/
CT should be performed to verify normali-
zation of the liver uptake after the required
phlebotomies and the normalization of the
iron parameters. The evidences of correla-
tion between iron concentration and high
18F-FDG uptake could have important impli-
cations also on neurodegenerative disease
characterized by iron accumulation in the
specific brain areas such asNBIA, Parkinson
disease, Alzheimer disease, Huntington dis-
ease, and multiple sclerosis.
In conclusion, we compliment with
the authors for the important observa-
tion of high 18F-FDG liver uptake in a pa-
tient with HH opening a new door to a
possible important tool for the diagnosis
of this pathology.ACKNOWLEDGMENTS
The authors thank God for enabling them to
work for people who are ill.
Isabella Zanella, PhD




Civic Hospital of Brescia
Brescia, Italy
Francesco Bertagna, MD
Department of Nuclear Medicine
University of Brescia and Spedali Civili of Brescia
Brescia, Italy
Giorgio Biasiotto, PhD
Department of Molecular and Translational
Medicine, University of Brescia
and Biotechnology/3rd Laboratory
Department of Diagnostics
Civic Hospital of Brescia
Brescia, Italy
giorgio.biasiotto@unibs.it
Conflicts of interest and sources of
funding: none declared.
REFERENCES
1. Pietrangelo A. Hereditary hemochromatosis—a
new look at an old disease. N Engl J Med. 2004;
350:2383–2397.www.nuclearmed.com 261
rved.
Clinical Nuclear Medicine • Volume 41, Number 3, March 20162. Camaschella C, Roetto A, De Gobbi M. Juve-
nile hemochromatosis. Semin Hematol. 2002;
39:242–248.
3. Biasiotto G, Camaschella C, Forni GL, et al.
New TFR2 mutations in young Italian patients
with hemochromatosis. Haematologica. 2008;
93:309–310.262 www.nuclearmed.com
Copyright4. Pietrangelo A. The ferroportin disease. Blood
Cells Mol Dis. 2004;32:131–138.
5. Zanella I, Rossini A, Di Lorenzo D, et al. Hered-
itary hemochromatosis: the same old song.
Blood Cells Mol Dis. 2015;55:216–217.
6. Infante JR, Moreno M, Rayo JI, et al. High
liver FDG uptake on PET/CT in patient© 2015 Wolt
 © 2016 Wolters Kluwer Health, Inc. All rights resewith lymphoma diagnosed with hereditary
hemochromatosis. Clin Nucl Med. 2015;40:
538–539.
7. Ito K, Minamimoto R, Morooka M, et al. A case
of secondary hemochromatosis with high uptake
of liver in F-18 FDG PET/CT imaging.Clin Nucl
Med. 2011;36:606–608.ers Kluwer Health, Inc. All rights reserved.
rved.
